Contraception
Volume 76, Issue 6 , Pages 425-431 , December 2007

Bone status after cessation of use of injectable progestin contraceptives

  • Lynn Rosenberg

      Affiliations

    • Slone Epidemiology Center at Boston University, Boston, MA 02215-1201, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 617 734 6006; fax: +1 617 738 5119.
    web address
    • ,
  • Yuqing Zhang

      Affiliations

    • Slone Epidemiology Center at Boston University, Boston, MA 02215-1201, USA
    • ,
  • Deborah Constant

      Affiliations

    • Women’s Health Research Unit, University of Cape Town, Cape Town 7925, South Africa
    • ,
  • Diane Cooper

      Affiliations

    • Women’s Health Research Unit, University of Cape Town, Cape Town 7925, South Africa
    • ,
  • Asgar A. Kalla

      Affiliations

    • Department of Medicine, University of Cape Town, Cape Town 7925, South Africa
    • ,
  • Lisa Micklesfield

      Affiliations

    • Exercise and Sports Medicine Research Unit, University of Cape Town, Cape Town 925, South Africa
    • ,
  • Margaret Hoffman

      Affiliations

    • Women’s Health Research Unit, University of Cape Town, Cape Town 7925, South Africa

Received 10 August 2007 ,Accepted 23 August 2007.

References 

  1. Rosenfield A, Maine D, Rochat R, Shelton J, Hatcher RA. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?. JAMA. 1983;249:2922–2928
  2. Garza-Flores J, Hall PE, Perez-Palacios G. Long-acting hormonal contraceptives for women. J Steroid Biochem Mol Biol. 1991;40:697–704
  3. Stone R. Depo-Provera. Controversial contraceptive wins approval from FDA panel. Science. 1992;256:1754
  4. Mishell DR. Long-acting contraceptive steroids, postcoital contraceptives and antiprogestins. In:  Mishell DR,  Davajan V,  Lobo RA editor. Infertility, contraception, and reproductive endocrinology. 3rd ed.. Boston: Blackwell Scientific Publications; 1991;p. 871–894
  5. Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab. 1977;44:32–38
  6. Davis AJ. Use of depot medroxyprogesterone acetate contraception in adolescents. J Reprod Med. 1996;41:407–413
  7. Jeppson S, Gershagen S, Johansson EDS, Rannevik G. Plasma levels of medroxyprogesterone acetate (MPA), sex hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depot-MPA as a contraceptive agent. Acta Endocrinol. 1982;99:339–343
  8. Richelson LS, Wahner HW, Melton LJ, Riggs BL. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med. 1984;311:1273–1275
  9. Cann CE, Genant HK, Ettinger B, Gordan GS. Spinal mineral loss in oophorectomized women. Determination by quantitative computed tomography. JAMA. 1980;244:2056–2059
  10. Cann CE, Martin MC, Genant HK, Jaffe RB. Decreased spinal mineral content in amenorrheic women. JAMA. 1984;251:626–629
  11. Drinkwater BL, Nilson K, Chesnut CH, Bremner WJ, Shainholtz S, Southworth MB. Bone mineral content of amenorrheic and eumenorrheic athletes. N Engl J Med. 1984;311:277–281
  12. Vaananen HK, Harkonen PL. Estrogen and bone metabolism. Maturitas. 1996;23(Suppl):S65–S69
  13. Melton LJ, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. Am J Epidemiol. 1989;129:1000–1011
  14. Cauley JA, Danielson ME. Osteoporosis. In:  Goldman MB,  Hatch MC editor. Women and health. San Diego (Calif): Academic Press; 2000;p. 1182–1192
  15. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ. 1991;303:13–16
  16. Cundy T, Farquhar CM, Cornish J, Reid IR. Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women. J Clin Endocrinol Metab. 1996;81:1014–1017
  17. Taneepanichskul S, Intaraprasert S, Theppisai U, Chaturachinda K. Bone mineral density during long-term treatment with Norplant implants and depot medroxyprogesterone acetate. A cross-sectional study of Thai women. Contraception. 1997;56:153–155
  18. Bahamondes L, Perrotti M, Castro S, Faundes D, Petta C, Bedone A. Forearm bone density in users of Depo-Provera as a contraceptive method. Fertil Steril. 1999;71:849–852
  19. Gbolade B, Ellis S, Murby B, Randall S, Kirkman R. Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol. 1998;105:790–794
  20. Scholes D, Lacroix AZ, Ott SM, Ichikawa LE, Barlow WE. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol. 1999;93:233–238
  21. Petitti DB, Piaggio G, Mehta S, Cravioto MC, Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol. 2000;95:736–744
  22. Wanichsetakul P, Kamudhamas A, Watanaruangkovit P, Siripakarn Y, Visutakul P. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception. 2002;65:407–410
  23. Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2004;82:1580–1586
  24. Paiva LC, Pinto-Neto AM, Faundes A. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive. Contraception. 1998;58:351–355
  25. Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf). 1998;49:615–618
  26. Tang OS, Tang G, Yip PS, Li B. Further evaluation on long-term depot-medroxyprogesterone acetate use and bone mineral density: a longitudinal cohort study. Contraception. 2000;62:161–164
  27. Merki-Feld GS, Neff M, Keller PJ. A prospective study on the effects of depot medroxyprogesterone acetate on trabecular and cortical bone after attainment of peak bone mass. BJOG. 2000;107:863–869
  28. Berenson AB, Radecki CM, Grady JJ, Rickert VI, Thomas A. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol. 2001;98:576–582
  29. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr. 1996;129:671–676
  30. Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception. 2006;74:90–99
  31. Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. Contraception. 2006;73:470–487
  32. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology. 2002;13:581–587
  33. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005;159:139–144
  34. Clark MK, Sowers M, Levy B, Nichols S. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2006;86:1466–1474
  35. Cundy T, Cornish J, Evans MC, Roberts H, Reid IR. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ. 1994;308:247–248
  36. d'Arcangues C. WHO statement on hormonal contraception and bone health. Contraception. 2006;73:443–444
  37. Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol. 2000;151:396–403
  38. Gregg EW, Kriska AM, Salamone LM, et al. The epidemiology of quantitative ultrasound: a review of the relationships with bone mass, osteoporosis and fracture risk. Osteoporos Int. 1997;7:89–99
  39. Christiansen C, Riis BJ, Nilas L, Rodbro P, Deftos L. Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis. Lancet. 1985;2:800–801
  40. Sowers M, Jannausch M, Scholl T, Schall J. The reproducibility of ultrasound bone measures in a triethnic population of pregnant adolescents and adult women. J Bone Miner Res. 1998;13:1768–1774
  41. Daniels ED, Pettifor JM, Schnitzler CM, Moodley GP, Zachen D. Differences in mineral homeostasis, volumetric bone mass and femoral neck axis length in black and white South African women. Osteoporos Int. 1997;7:105–112
  42. Frost ML, Blake GM, Fogelman I. Quantitative ultrasound and bone mineral density are equally strongly associated with risk factors for osteoporosis. J Bone Miner Res. 2001;16:406–416
  43. Gluer CC, Barkmann R, Heller M. Quantitative ultrasound. State of the art 1999. Radiologe. 1999;39:213–221
  44. Cummings SR, Black D. Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med. 1995;98(Supply):24S–28S
  45. Toyras J, Kroger H, Jurvelin JS. Bone properties as estimated by mineral density, ultrasound attenuation, and velocity. Bone. 1999;25:725–731

☆ The present study was supported by grant HD042360 from the National Institute of Child Health and Human Development.

PII: S0010-7824(07)00414-3

doi: 10.1016/j.contraception.2007.08.010

Contraception
Volume 76, Issue 6 , Pages 425-431 , December 2007

Article Tools

* Image Usage & Resolution